---
document_datetime: 2025-04-24 12:07:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/regkirona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: regkirona-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9577635
conversion_datetime: 2025-12-25 04:29:39.377817
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

| Application number   | Scope                                                                                                                                         | Opinion/ Notification 1 issued on product   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                           |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------|
| IB/0021              | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation | 25/10/2024                                  | n/a                                         |                                  |                                   |
| PSUSA/10964 /202402  | Periodic Safety Update EU Single assessment - regdanvimab (Regkirona)                                                                         | 05/09/2024                                  | n/a                                         |                                  | PRAC Recommendation - maintenance |

Regkirona Procedural steps taken and scientific information after the authorisation Application number Scope Commission Decision Issued 2  / amended Product Information affected 3 Summary IB/0021 C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation n/a PSUSA/10964 /202402 Periodic Safety Update EU Single assessment regdanvimab (Regkirona) n/a PRAC Recommendation - maintenance Medicinal product no longer authorised

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<div style=\"page-break-after: always\"></div>

| PSUSA/10964 /202308   | Periodic Safety Update EU Single assessment - regdanvimab (Regkirona)                                                                                                                                                | 07/03/2024   | n/a        | PRAC Recommendation - maintenance   |
|-----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------------------------|
| IB/0019               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                               | 26/02/2024   | n/a        | authorised                          |
| PSUSA/10964 /202302   | Periodic Safety Update EU Single assessment - regdanvimab (Regkirona)                                                                                                                                                | 31/08/2023   | n/a        | PRAC Recommendation - maintenance   |
| IB/0016               | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                  | 24/08/2023   | 10/10/2023 | SmPC longer                         |
| IA/0015               | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                        | 04/05/2023   | n/a no     |                                     |
| IB/0012/G             | This was an application for a group of variations. B.II.f.1.e - Stability of FP - Change to an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol Medicinal product | 24/04/2023   | n/a        |                                     |
| IA/0013               | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                        | 31/03/2023   | 10/10/2023 | SmPC                                |
| PSUSA/10964 /202208   | Periodic Safety Update EU Single assessment - regdanvimab (Regkirona)                                                                                                                                                | 16/03/2023   | n/a        | PRAC Recommendation - maintenance   |

<div style=\"page-break-after: always\"></div>

| IB/0010             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol           | 12/12/2022   | 10/10/2023   | SmPC                   | authorised                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0008             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                             | 10/11/2022   | 10/10/2023   | SmPC                   |                                                                                                                                                                                                                                                                                                                                                                                                        |
| IB/0009             | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                        | 27/10/2022   | n/a          | longer                 |                                                                                                                                                                                                                                                                                                                                                                                                        |
| II/0005             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data product                                                                     | 13/10/2022   | n/a no       |                        |                                                                                                                                                                                                                                                                                                                                                                                                        |
| PSUSA/10964 /202202 | Periodic Safety Update EU Single assessment - regdanvimab (Regkirona)                                                                                                                         | 01/09/2022   | n/a          |                        | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                      |
| IB/0007             | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Medicinal | 21/07/2022   | 10/10/2023   | SmPC, Labelling and PL | To update the product information as follows: - To update Section 6.3 of the SmPC to extend the shelf-life of the finished product from 18 months to 21 months. - To introduce editorial changes including deletion of the QR code from Annex III (Labelling, section 18 and Package Leaflet, section 6) and to implement linguistic review comments from the German and Hungarian health authorities. |
| II/0004             | Update of section 5.1 of the SmPC to include in vitro                                                                                                                                         | 19/05/2022   | 25/05/2022   | SmPC                   | In vitro data suggest that the SARS-CoV-2 B.1.1.529                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | neutralization activity of regdanvimab against the SARS-CoV-2 B.1.1.529 (Omicron) variant of concern based on report REP-ND22-047. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                           |            |            |                       | (Omicron) variant shows reduced susceptibility against regdanvimab (Regkirona).                      |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|------------------------------------------------------------------------------------------------------|
| IB/0003/G | This was an application for a group of variations. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol B.II.f.1.e - Stability of FP - Change to an approved stability protocol | 13/04/2022 | 25/05/2022 | SmPC longer           | authorised                                                                                           |
| II/0002   | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol product                                             | 24/03/2022 | n/a no     |                       |                                                                                                      |
| IB/0001   | To extend the shelf-life of the finished product from 1 year to 15 months when stored at 2째C to 8째C. B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol Medicinal             | 13/12/2021 | 25/05/2022 | SmPC, Annex II and PL | To extend the shelf-life of the finished product from 1 year to 15 months when stored at 2째C to 8째C. |